Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
Invivyd (Nasdaq: IVVD) has appointed Kristie Kuhl as Chief Communications Officer to lead the company's communications and patient advocacy initiatives. Kuhl, recognized in PRWeek's 2024 Health Influencer 30, joins from Zeno Group where she served as Global Managing Director of Health & Wellness.
In her new role, Kuhl will focus on advancing understanding of Invivyd's work in developing monoclonal antibodies for viral disease prevention and treatment, while building stakeholder trust and supporting company growth. Her appointment comes at a strategic time as Invivyd aims to strengthen its scientific credibility and relationships with key healthcare stakeholders.
Invivyd (Nasdaq: IVVD) ha nominato Kristie Kuhl come Chief Communications Officer per guidare le iniziative di comunicazione e advocacy per i pazienti dell'azienda. Kuhl, riconosciuta nella PRWeek's 2024 Health Influencer 30, proviene dal Zeno Group dove è stata Global Managing Director di Health & Wellness.
Nel nuovo ruolo, Kuhl si concentrerà sul promuovere la comprensione del lavoro di Invivyd nello sviluppo di anticorpi monoclonali per la prevenzione e il trattamento delle malattie virali, costruendo la fiducia delle parti interessate e supportando la crescita dell'azienda. La sua nomina arriva in un momento strategico, poiché Invivyd intende rafforzare la propria credibilità scientifica e le relazioni con i principali stakeholder sanitari.
Invivyd (Nasdaq: IVVD) ha nombrado a Kristie Kuhl como directora de comunicaciones para liderar las iniciativas de comunicaciones y defensa de los pacientes de la empresa. Kuhl, reconocida en PRWeek's 2024 Health Influencer 30, procede desde Zeno Group, donde se desempeñó como Global Managing Director de Health & Wellness.
En su nuevo cargo, Kuhl se centrará en avanzar la comprensión del trabajo de Invivyd en el desarrollo de anticuerpos monoclonales para la prevención y el tratamiento de enfermedades virales, al tiempo que construye la confianza de las partes interesadas y apoya el crecimiento de la empresa. Su nombramiento llega en un momento estratégico, ya que Invivyd busca fortalecer su credibilidad científica y las relaciones con los principales actores del cuidado de la salud.
Invivyd (Nasdaq: IVVD)가 Kristie Kuhl를 최고 커뮤니케이션 책임자(Chief Communications Officer)로 임명하여 회사의 커뮤니케이션 및 환자 옹호 이니셔티브를 이끌게 했습니다. Kuhl은 PRWeek의 2024년 헬스 인플루언서 30로 인정받았으며, Health & Wellness의 글로벌 매니징 디렉터로 재직하던 Zeno Group에서 합류했습니다.
새로운 역할에서 Kuhl은 바이러스성 질환 예방 및 치료를 위한 단클론 항체 개발에 대한 Invivyd의 노력을 이해시키고 이해관계자 간의 신뢰를 구축하며 회사의 성장을 지원하는 데 집중할 것입니다. 이 임명은 Invivyd가 과학적 신뢰도와 주요 보건 이해관계자와의 관계를 강화하려는 전략적 시기에 이뤄졌습니다.
Invivyd (Nasdaq: IVVD) a nommé Kristie Kuhl comme Directrice des Communications pour diriger les initiatives de communication et de plaidoyer des patients de l'entreprise. Kuhl, reconnue dans le PRWeek's 2024 Health Influencer 30, arrive en provenance de Zeno Group où elle était Global Managing Director Health & Wellness.
Dans son nouveau rôle, Kuhl se concentrera sur l'avancement de la compréhension du travail d'Invivyd dans le développement d'anticorps monoclonaux pour la prévention et le traitement des maladies virales, tout en renforçant la confiance des parties prenantes et en soutenant la croissance de l'entreprise. Sa nomination intervient à un moment stratégique alors qu'Invivyd vise à renforcer sa crédibilité scientifique et ses relations avec les principaux acteurs de la santé.
Invivyd (Nasdaq: IVVD) hat Kristie Kuhl als Chief Communications Officer ernannt, um die Kommunikations- und Patientenvertretungsinitiativen des Unternehmens zu leiten. Kuhl, anerkannt in PRWeeks 2024 Health Influencer 30, kommt von der Zeno Group, wo sie Global Managing Director Health & Wellness war.
In ihrer neuen Rolle wird Kuhl darauf fokussieren, das Verständnis für Invivyds Arbeit bei der Entwicklung von monoklonalen Antikörpern zur Vorbeugung und Behandlung viraler Krankheiten voranzutreiben, während sie das Vertrauen der Stakeholder aufbaut und das Unternehmenswachstum unterstützt. Ihre Ernennung fällt in eine strategische Phase, in der Invivyd seine wissenschaftliche Glaubwürdigkeit und Beziehungen zu wichtigen Gesundheits-Stakeholdern stärken will.
Invivyd (بورصة ناسداك: IVVD) تعي كريستي كوهل رئيسة الاتصالات التنفيذي فقيادة مبادرات الشركة في مجال الاتصالات ودفاع المرضى. وتشتهر كوهل بتقييم PRWeek's 2024 Health Influencer 30، وتأتي من Zeno Group حيث كانت المديرة العالمية لإدارة الصحة والعافية.
في دورها الجديد، ستتركز كوهل على تعميق فهم عمل Invivyd في تطوير الأجسام المضادة أحادية النسيلة للوقاية من الأمراض الفيروسية ومعالجتها، وبناء ثقة أصحاب المصلحة ودعم نمو الشركة. وتأتي ترقيةها في وقت استراتيجي إذ تسعى Invivyd إلى تعزيز مصداقيتها العلمية وعلاقاتها مع أصحاب المصلحة الرئيسيين في الرعاية الصحية.
Invivyd (纳斯达克代码：IVVD) 已任命 Kristie Kuhl 为首席对外沟通官，领导公司的沟通及患者倡导工作。Kuhl 曾被列入 PRWeek 2024 Health Influencer 30，此前任职于 Zeno Group，担任全球健康与养生事业部总经理。
在新职位上，Kuhl 将专注于提升对 Invivyd 在开发单克隆抗体用于病毒性疾病预防与治疗方面工作的理解，促进各方信任并支持公司增长。此次任命正逢 Invivyd 致力于提升科学可信度并加强与关键医疗保健利益相关者关系的战略时期。
- Appointment of an experienced healthcare communications leader with industry recognition
- Strategic focus on strengthening stakeholder communications and trust
- None.
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease.
Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek’s 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm’s healthcare practice globally.
“I’m thrilled to join Invivyd at such a pivotal time for the company, and for the patients and communities we serve,” said Kristie Kuhl, Chief Communications Officer at Invivyd. “Invivyd’s science-led approach and commitment to providing protection from serious viral diseases demand bold, clear, and compassionate communications. I look forward to partnering with our leadership and teams to advance understanding of our work, deepen stakeholder trust, and support the company’s growth.”
“Kristie’s track record building high-impact healthcare narratives and leading teams through dynamic environments is critical to Invivyd as we move forward with our mission,” said Marc Elia, Chairman of the Invivyd Board of Directors. “American healthcare, and especially prevention of viral disease, requires that companies like Invivyd build unimpeachable scientific credibility and trust with patients, vulnerable populations, HCPs, payor systems and government agencies, and I look forward to partnering with Kristie to immediately accelerate our efforts.”
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “estimates,” “hypothesizes,” “intends,” “potential,” “predicts” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company’s mission of providing monoclonal antibodies for the prevention and treatment of viral disease; the anticipated contributions of the company’s Chief Communications Officer and her expectations to advance understanding of the company’s work, deepen stakeholder trust, and support the company’s growth; the company’s efforts to build scientific credibility and trust; the company’s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the company’s discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data; how long the EUA granted by the U.S. FDA for a mAb in the company’s pipeline will remain in effect and whether the EUA is revised or revoked by the U.S. FDA; whether the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in the regulatory environment; the outcome of the company’s engagement with regulators; changes in expected or existing competition; the company’s reliance on third parties; the complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
Who is Kristie Kuhl and what is her new role at Invivyd (IVVD)?
What will be Kristie Kuhl's main responsibilities at Invivyd (IVVD)?
What is Invivyd's (IVVD) main business focus?
Why did Invivyd (IVVD) appoint a new Chief Communications Officer?
